Phase 2 open-label RCT of 60 palliative care patients with terminal agitation: intranasal and subcutaneous midazolam 5 mg both reduced median RASS-PAL scores by at least 1 point at 5 and 20 min; intranasal gave higher plasma levels (secondary outcome).
RCTn = 60
Hirschinger et al. A randomized controlled clinical trial of intranasal versus subcutaneous midazolam for agitation in terminal illness (MinTU study)